Another study indicated that PTEN-mutant endometrioid endometrial carcinoma cells may not be sufficiently sensitive to the inhibition of p110β alone and that combined targeted agents may be required for effective treatment [93]. The gene discussed is PTEN; the disease is endometrial endometrioid carcinoma.